Harvard Business Review

AUGUST 17, 2012

Most of its sales are in the developing world (including 40% in Africa) — where it sells its HIV drugs for about $350 per year per patient — yet it is as profitable as the pharma giants of Europe, North America, and Japan. It has doubled its market cap in the five years and sales reached almost $1.5

Company 12

Company Pharmaceuticals Business Model Fixed Costs 12

Harvard Business Review

DECEMBER 12, 2012

Based on data covering the period from 2005 to 2011, it charts how globalization has evolved since the onset of the financial crisis at the global, regional, and national levels. Capital markets are fragmenting and while merchandise trade recovered strongly since 2009, the intensity of services trade has remained stagnant.

Report 15

Report Merchandising GDP Globalization 15

Harvard Business Review

NOVEMBER 8, 2017

The health care system in the United States, with its technological prowess and massive infrastructure, often serves as a reference point for rapidly developing economies around the world while they build their own medical systems. Over the same period, pharmaceutical exports have doubled. Insight Center. Transforming Health Care.

Health Care 8

Health Care Tourism Pharmaceuticals Cost 8

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. By the end of October in 2010, the market value of the 100 constituent stocks reached 582 billion RMB, accounting for 31% of the total market value of the Shanghai Stock Exchange's A shares. Stay tuned.

Long-term 15

Long-term Sample Report Pharmaceuticals 15

Harvard Business Review

JUNE 16, 2016

To understand the nature of the problem, let’s look at how penicillin was brought to market. The initial breakthrough came in 1987, but the first drug wasn’t approved until 2011. The Joint Center For Energy Storage Research (JCESR) has a five-year mandate to develop next generation battery technologies.

Technology 8

Technology Venture Capitalist Supply Chain Innovation 8

Harvard Business Review

MAY 17, 2012

Each year, twenty million babies worldwide are born prematurely or with a low birth weight, and four million of them die, most in developing nations. Unfortunately, current options for warming babies in developing nations are either expensive or unsafe. In 2011, Embrace piloted the product in India, where 1.2

Incubator 11

Incubator Business Model Entrepreneur Cost 11

Harvard Business Review

SEPTEMBER 14, 2011

We recently visited the brand-new R&D lab of Dr Reddy's , one of India's leading pharmaceutical firms. In 2008, Dr Reddy's acquired Chirotech, Dow Chemical's R&D unit, for $32 million, and in April 2011 relocated it to a new 33,000 sq. This lab isn't located in Bangalore or Hyderabad (where Dr Reddy's is headquartered) but in.

Globalization 10

Globalization Innovation Decentralization Chemicals 10

Harvard Business Review

DECEMBER 14, 2015

“There was this one instance where the market tanked and there was panic on the desk. Thanks to my meditation practice, I was able to keep my composure and propose solutions to reduce the impact of the market crash.” “Thanks to meditation I have developed patience.” The trading desk was an organized riot.

CEO 8

CEO Emotional Intelligence Cooper Pharmaceuticals 8

Harvard Business Review

FEBRUARY 24, 2015

The first category is exogenous factors over which the business has little control: the growth of the markets into which it sells; the competitive intensity and thus the average profitability of the industry in which it operates; or the fragmentation of its industry and thus the scope for a growth-by-acquisition approach.

Chemicals 8

Chemicals How To Kahneman Reputation 8

Harvard Business Review

JUNE 29, 2015

If you ask someone who works in finance (as I had to) about PE and innovation, he or she will likely tell you that PE sponsors aren’t looking for the next big thing—they’re looking for companies that are dominant in a market, aren’t risky, and have a predictable and steady stream of cash to pay back debt.

LBO 8

LBO Innovation Sample Short-term 8

Strategy Driven

JANUARY 24, 2011

Execution Gap Maker #2: Nokia Nokia’s share of the worldwide market for mobile phones continued to slip in 2010. Why was this once-dominant player unable to execute and maintain its market position? It developed the NOOK and has devoted significant space in its retail stores to display and promote it, and it has a broad online library.

Execution 67

Execution Company 360-Degree Feedback Cooper 67

Harvard Business Review

NOVEMBER 20, 2015

He is poised to become the leader in this segment of a multi-billion dollar market. Compliance is crucial for pharmaceutical makers such as Abbott and Amgen – a “ Form 483 ” warning from an FDA inspector can shut down a drug facility in an instant and even land top executives in jail.

Supply Chain 8

Supply Chain Collins Golden Handcuff Pharmaceuticals 8

Harvard Business Review

MAY 10, 2013

As noted management expert Geoffrey Moore told me with respect to high-velocity competition, "I''m not sure you ever want to be in the public markets." Its RAZR thin phone was a huge success in the mid-2000''s, and the market raved. Take Motorola, for instance. Take Motorola, for instance.

Venture Capitalist 8

Venture Capitalist Restructuring Competitive Advantage Short-term 8

Harvard Business Review

JUNE 21, 2017

For all but the most prevalent of cancers, no single cancer center or institution has enough data for researchers to gain insight into the genetic mutations and molecular abnormalities that ignite the development of cancer and fuel its progression. Insight Center. For some, that meant flying across the country several times.

Metrics 8

Metrics Health Care Learning-by-Doing Education 8

Harvard Business Review

SEPTEMBER 11, 2014

That means new technologies and new competitors are hitting the market at an unprecedented rate. Finally, industries in the upper-right quadrant — such as software, pharmaceuticals, and medical equipment — face high uncertainty in both demand and technology. To illustrate this, consider that patent applications in the U.S.

Uncertainty 22

Uncertainty Industry Bottom-up Technology 22

Harvard Business Review

MAY 25, 2017

The pipeline for new drugs is bursting, and new devices and tools in the rapidly emerging digital health space will come to market more quickly. Investors are already keenly focused on this area, with many startups competing for a slice of the market. A third growth area is in EHRs and digital health applications.

Health Care 9

Health Care Trends Venture Funding Technology 9